An investigation on behalf of investors of Amarin Corporation plc (NASDAQ: AMRN) shares over potential securities laws violations by Amarin Corporation plc and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amarin Corporation plc (NASDAQ: AMRN) concerning whether a series of statements by Amarin Corporation plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Ireland based Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. On August 8, 2019, Amarin Corporation plc announced that it received notice from the FDA that it plans to hold an advisory committee meeting, tentatively scheduled for November 14, 2019, in connection with its review of the pending supplemental new drug application for expansion of Vascepa. Amarin Corporation plc stated that the FDA's deadline for making an approval decision on Vascepa would likely be extended.
Just one week earlier, on July 31, 2019, Amarin Corporation plc said it was unlikely that the FDA would proceed with an advisory panel review regarding approval of Vascepa and anticipated a September 28, 2019 approval.

Shares of Amarin Corporation plc (NASDAQ: AMRN) declined to as low as $13.76 per share on August 12, 2019.